Last mentioned: Feb 26, 2026
The Q4 2025 earnings reports from leading biotech and specialty pharma firms reveal a sector-wide transition toward commercial-stage CRISPR therapies and high-growth radiopharmaceuticals. Key players like Intellia and Lantheus are setting the pace for 2026, while specialty firms focus on operational efficiency and non-opioid alternatives.
Lantheus Holdings and Heron Therapeutics both reported mixed fourth-quarter financial results, highlighting a period of transition for the mid-cap biotech sector. While both companies provided initial FY26 outlooks, market attention is shifting toward their respective commercial scaling efforts and pipeline execution.
As the Q4 2025 earnings season commences, Delcath Systems, Butterfly Network, Heron Therapeutics, and Lantheus Holdings are under intense scrutiny regarding their commercial execution and path to profitability. Investors are particularly focused on Delcath's HEPZATO KIT rollout and Lantheus's ability to maintain its dominance in the competitive radiopharmaceutical market.